SCHEDULE 13G/A: Bristol Myers Squibb and Celgene Disclose 1.9% Passive Stake in Celularity Inc.
Beneficial Ownership Disclosure
Bristol Myers Squibb Company and its subsidiary Celgene Corporation have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 1.9% in Celularity Inc.'s Class A Common Stock.
Summary
- Bristol Myers Squibb Company (BMS) and its wholly-owned subsidiary Celgene Corporation jointly filed an Amendment No. 1 to Schedule 13G regarding their beneficial ownership in Celularity Inc.
- As of December 31, 2024, the reporting persons collectively beneficially own 426,372 shares of Celularity Inc.'s Class A Common Stock.
- This ownership represents 1.9% of Celularity Inc.'s Class A Common Stock outstanding.
- The percentage is calculated based on 22,484,239 shares of Class A common stock outstanding as of December 2, 2024, as reported in Celularity Inc.'s Form 10-Q filed on December 6, 2024.
- Celgene Corporation is the record holder of all 426,372 shares, and BMS is deemed to beneficially own these shares through its subsidiary.
- The filing indicates that the securities were not acquired and are not held for the purpose or effect of changing or influencing the control of Celularity Inc.
Sentiment
Score: 5
Explanation: The document is a factual, regulatory filing (Schedule 13G) disclosing beneficial ownership. It contains no forward-looking statements, performance metrics, or qualitative assessments that would indicate a positive or negative sentiment.
Future Outlook
NA
Industry Context
This filing is a routine disclosure of beneficial ownership by a large pharmaceutical company (Bristol Myers Squibb/Celgene) in a biotechnology firm (Celularity Inc.). Such passive stakes are common and typically do not indicate strategic shifts or direct operational involvement, but rather a financial investment or a legacy holding from previous transactions.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional holder's passive stake, confirming their continued, non-controlling interest in the company.
Key Dates
| Date | Description |
|---|---|
| 2024-12-02 | Date as of which 22,484,239 shares of Class A common stock were reported outstanding in Celularity's Form 10-Q. |
| 2024-12-06 | Date Celularity Inc. filed its Form 10-Q with the SEC. |
| 2024-12-31 | Date of event which required the filing of this statement (end of reporting period). |
| 2025-02-14 | Date the Schedule 13G Amendment No. 1 was signed and filed. |
Keywords
Celularity Inc., Bristol Myers Squibb, Celgene Corporation, Schedule 13G, Beneficial Ownership, Class A Common Stock, SEC Filing, Passive Investment
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.